Perjeta (pertuzumab)

€2,988.60
In stock
SKU
Perjeta (pertuzumab)

How to buy Perjeta (pertuzumab): You can order Perjeta (pertuzumab) from TheSocialMedwork if the medicine has not been approved or is not available in your country. We help patients and doctors get access to medicines at the lowest price worldwide.

Oncology Breast Cancer
Marketing Authorisation Holder Roche Registration Limited
Mode of Action HER2/neu receptor antagonist (immunotherapy)
Administration Intravenous
Regulatory agency approval European Medical Agency (EMA), European Union, Food and Drug Administration (FDA), USA, Therapeutic Goods Administration (TGA), Australia
Strength 30 milligram / millilitre
Package 1 vial of 420 mg/14 ml - Vials

What is Perjeta (pertuzumab) for?

Perjeta (pertuzumab) is indicated for the treatment of HER2 positive breast cancer in patients with metastatic cancer or as neoadjuvant treatment for patients with locally advanced, inflammatory, or early stage breast cancer as part of a complete treatment regimen for early breast cancer1,2,3.

How does Perjeta (pertuzumab) work?

Perjeta (pertuzumab) is used in combination with trastuzumab and docetaxel (other cancer medicines) for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease1,2,3.

It is also used in combination with trastuzumab and chemotherapy as neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer as part of a complete treatment regimen for early breast cancer1,2,3.

Is Perjeta (pertuzumab) approved?

Perjeta (pertuzumab) was approved for HER2 positive breast cancer in metastatic patients or as neoadjuvant therapy by:

  • FDA (USA) on June 12, 20125
  • EMA (EU) on March 4, 20132
  • TGA (AUS) on May 6, 20133

How do I take Perjeta (pertuzumab)?

The standard dosage is:

  • Initial dose: 840 mg administered as a 60-minute intravenous infusion
  • Following infusions: 420 mg administered as a 30 to 60-minute intravenous infusion every 3 weeks.

Patients with metastatic breast cancer should be treated with pertuzumab and trastuzumab until disease progression or unmanageable toxicity.

Patients in neoadjuvant treatment of breast cancer should be administered pertuzumab every 3 weeks for 3 to 6 cycles before surgery.

Complete information about Perjeta (pertuzumab) dosage and administration can be found in the resources section5,2,3.

Note: Consult your treating doctor for personalised dosing.

Common side effects of Perjeta (pertuzumab)

The most common side effects with Perjeta given with trastuzumab and chemotherapy are4:

  • diarrhoea
  • alopecia (hair loss)
  • nausea
  • neutropenia (low levels of neutrophils, a type of white blood cell important for fighting infections).

Serious side effects of Perjeta (pertuzumab)

The most common serious side effects include4:

  • febrile neutropenia (low levels of neutrophils with fever)
  • serious diarrhoea
  • leucopenia (low white blood cell counts)
  • neutropenia.


More Information
Working ingredient Pertuzumab
Shipping method Cold chain (temperature controlled)
Package 1 vial of 420 mg/14 ml -
Therapeutic Area Oncology
Oncology Breast Cancer
Indication Metastatic or locally advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer
Administration Intravenous
Mode of Action HER2/neu receptor antagonist (immunotherapy)
Strength 30
Regulatory agency approval European Medical Agency (EMA), European Union, Food and Drug Administration (FDA), USA, Therapeutic Goods Administration (TGA), Australia
Marketing Authorisation Holder Roche Registration Limited

The approvals of pertuzumab for metastatic breast cancer were based on a multicentre, randomised, double-blind, placebo-controlled phase III clinical trial (CLEOPATRA - WO20698) which included 808 patients with HER2-positive metastatic or locally recurrent unresectable breast cancer. Patients received either placebo, trastuzumab and docetaxel or pertuzumab, trastuzumab and docetaxel. The addition of pertuzumab to the treatment resulted in an extension of the median progression-free survival (PFS) by over 6 months (18.5 months vs 12.4 months)1,2,3. The median overall survival (OS) was 56.5 months in patients who took pertuzumab compared to 40.8 in patients who didn’t. The difference in overall response rate (ORR) was 10.8% in favour of pertuzumab (80.2% vs. 69.3%) with 5.5% complete responses (vs. 4.2%)2,3.

The approvals of pertuzumab as neoadjuvant treatment of breast cancer was based on two studies. The first, a phase II, multicentre, multinational randomised controlled trial (NEOSPHERE - WO20697) which involved 417 patients with newly diagnosed, early, inflammatory or locally advanced HER2-positive breast cancer who had not received prior trastuzumab, chemotherapy or radiotherapy. Patients were randomised to receive one of the following neoadjuvant regimens for 4 cycles prior to surgery:

  • trastuzumab plus docetaxel
  • Perjeta (pertuzumab) plus trastuzumab and docetaxel
  • Perjeta (pertuzumab) plus trastuzumab
  • Perjeta (pertuzumab) plus docetaxel2,3

The pathological complete response (pCR), defined as the absence of residual invasive disease in the breast and in the armpit lymph nodes at the completion of the neoadjuvant treatmentwas 39.3% [95% CI: 30, 49.2] in the group that took pertuzumab in combination with trastuzumab and docetaxel which was 2 to almost 4 times higher than the other combinations2,3.

The second study (TRYPHAENA - BO22280) a multicentre, randomised phase II clinical trial, involved 225 adult female patients with HER2-positive locally advanced, operable, or inflammatory breast cancer who had not received prior trastuzumab, chemotherapy or radiotherapy. Patients were randomly allocated to receive 1 of 3 neoadjuvant regimens prior to surgery as follows:

  • 3 cycles of FEC (5-Fluorouracil, epirubicin, and cyclophosphamide) followed by 3 cycles of docetaxel all in combination with Perjeta (pertuzumab) and trastuzumab,
  • 3 cycles of FEC alone followed by 3 cycles of docetaxel and trastuzumab in combination with Perjeta (pertuzumab)
  • 6 cycles of docetaxel, carboplatin, and trastuzumab in combination with Perjeta (pertuzumab).

The highest pCR rates were achieved in the last of the three groups, with a pCR rate of 66.2% [95% CI: 54.6; 76.6] vs 61.6% [95% CI: 49.5; 72.8] and 57.3% [95% CI: 45.4; 68.7] in the first and second group, respectively2,3.

Shipping Type Cold Chain
Shipping method Cold chain (temperature controlled)
This content has been reviewed by our medical doctor Jan de Witt.

How can we help you?

We're ready to answer any question!

Don't speak English? We also speak
Armenian, Bosnian, Bulgarian, Dutch, Filipino, German, Italian, Hebrew, Lithuanian, Portuguese, Russian, Serbian, Slovenian, Spanish, Swedish and Turkish.

 

Speak a different language?
Send us a message and we’ll do our best to translate.

 

Our guarantee: We will reply to all messages within 2 hours during office hours.

 

If you want to reach us via phone or chat, please visit our contact page

 

The Social Medwork is registered with the Dutch Ministry of Health in The Hague as an independent intermediary, Registration number 6730 BEM
100% legal and regulated
Registered with the Dutch Ministry of Health as an independent intermediary.

 

Registration number 6730 BEM
Secured logistics globally
• Standard and express delivery (DHL or UPS)
• 24/7 track & trace delivery
• Temperature regulated shipping
Secure payments
All payments are handled securely and are SSL encrypted.
We accept:
Bank transfer & Credit card

 

Patient reviews

 Tomasz Maćkowiak

During the transaction process I was very well informed by the TheSocialMedwork team. They have put as much of their effort to offer best service to me. Moreover the medicine I have ordered was imported two weeks earlier then it was expected. I highly recommend The Social Med Work.

Patient reviews

 Emina Mušović

Thank you for the wonderful cooperation! It's very reserved of us to say we're pleased because you really resolved all our doubts. The medicine has now arrived and we hope it helps. We know we were difficult, with the million different questions but well... That's all behind us now. Strongly recommended! :)

Patient reviews

 Mohamed Rahmat

I am fully satisfied with your online support service. Happy to deal with you.. fast & very fast support.. did not have to wait even 5 minutes! THANK YOU MEDWORK

Questions our patients are asking

visit our support page
You always need a prescription from a doctor based in your country. Other documents, such as an import license from the Ministry of Health, may be needed and depend on your country’s regulations. Contact us and we will provide you with all of the information about the required documents needed for your country.
For prescription medicines you will always need a prescription from your treating doctor. This is to ensure that your treatment is monitored and led by a doctor who is responsible for administering the medicine to you. The prescription is the evidence that your doctor gives you their medical support.
Your order will be shipped to you by our partner couriers, such as DHL, UPS and specialised medicine couriers. If you want us to use a specific courier please inform us when you place your order.
Yes. TheSocialMedwork is registered with the Dutch Ministry of Health as an independent medicines intermediary (registration number 6730 BEM). We always follow your country’s laws and regulations and will discuss any legal requirements with you. We only ship medicines when our patients have a prescription from their treating doctor.
By using TheSocialMedwork you will receive genuine medicines in perfect condition, no matter where you live.
Yes, you are welcome to visit us. We are located in the city centre of Amsterdam at the Herengracht 480. Contact us to schedule the best time for your visit.

 

You can order and receive your
medicine in 5 simple steps

1

Talk to your doctor

2

Place order
and send
prescription

3

Pay for order

4

Check documents
for delivery

5

Receive your medicine

Totally awesome!
Keep up the great
work you’re doing!


Dee Penfold - December 3, 2016
On TheSocialMedwork Facebook

Need a medicine that’s not
approved in your country?

We help patients, physicians and pharmacists acquire the latest life-changing medicines. Not available in your country? No problem - as long as it's approved by a reputable medical authority somewhere, we can help! Contact us today and our experienced team of qualified pharmacists and industry professionals will help you.


learn more
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.